Jonathan Haroon

Dr. Jonathan Haroon

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Medicine
Verified
Journal Article
Open access
JHJonathan Haroon
Jonathan Haroon
KJKaya Bs Jordan
Kaya Bs Jordan
Kennedy MahdaviKennedy Mahdavi
Kennedy Mahdavi
ERElisabeth Bs Rindner
Elisabeth Bs Rindner
SBSergio Bs Becerra
Sergio Bs Becerra
SJSheldon Jordan
Sheldon Jordan
Background: Alzheimer’s disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD. Methods: In this phase 2, open-label study, 23 patients with mild cognitive impairment or mild dementia received 20-mg oral NE3107 twice daily for 3 months. Primary endpoints assessed changes from baseline in neurophysiological health and oxidative stress (glutathione level) using advanced neuroimaging analyses. Secondary endpoints evaluated changes from baseline in neuropsychological health using cognitive assessments, including the 11-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment, Clinical Dementia Rating, Quick Dementia Rating Scale, Alzheimer’s Disease Composite Score, and Global Rating of Change (GRC). Exploratory endpoints assessed changes from baseline in neuroinflammation biomarkers (tumor necrosis factor alpha, TNF-α) and AD (amyloid beta and phosphorylated tau [P-tau]). Results: NE3107 was associated with clinician-rated improvements in cerebral blood flow and functional connectivity within the brain. In patients with MMSE ≥ 20 (mild cognitive impairment to mild AD; n = 17), NE3107 was associated with directional, but statistically nonsignificant, changes in brain glutathione levels, along with statistically significant improvements in ADAS-Cog11 (P = .017), Clinical Dementia Rating (P = .042), Quick Dementia Rating Scale (P = .002), Alzheimer’s Disease Composite Score (P = .0094), and clinician-rated GRC (P < .001), as well as in cerebrospinal fluid P-tau levels (P = .034) and P-tau:amyloid beta 42 ratio (P = .04). Biomarker analyses also demonstrated directional, but statistically non-significant, changes in plasma TNF-α, consistent with the expected mechanism of NE3107. Importantly, we observed a statistically significant correlation (r = 0.59) between improvements in TNF-α levels and ADAS-Cog11 scores (P = .026) in patients with baseline MMSE ≥ 20. Conclusion: Our results indicate that in this study NE3107 was associated with what appear to be positive neurophysiological and neuropsychological findings, as well as evidence of improvement in biomarkers associated with neuroinflammation and AD in patients diagnosed with dementia. Our findings are consistent with previous preclinical and clinical observations and highlight a central role of neuroinflammation in AD pathogenesis.

18 October 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JHJonathan Haroon
Jonathan Haroon
KAKaren Aboody
Karen Aboody
LFL. Flores
L. Flores
MMM. McDonald
M. McDonald
KMK. Mahdavi
K. Mahdavi
SJS. Jordan
S. Jordan
The blood–brain barrier (BBB) presents a significant challenge for targeted drug delivery. A proposed method to improve drug delivery across the BBB is focused ultrasound (fUS), which delivers ultrasound waves to a targeted location in the brain and is hypothesized to open the BBB. Furthermore, stem cell-derived exosomes have been suggested as a possible anti-inflammatory molecule that may have neural benefits, if able to pass the BBB. In the present study, transcranial low-intensity focused ultrasound (LIFU), without the use of intravenous microbubbles, was assessed for both (1) its ability to influence the BBB, as well as (2) its ability to increase the localization of intravenously administered small molecules to a specific region in the brain. In vivo rat studies were conducted with a rodent-customized 2 MHz LIFU probe (peak pressure = 1.5 MPa), and injection of labeled stem cell-derived exosomes. The results suggested that LIFU (without microbubbles) did not appear to open the BBB after exposure times of 20, 40, or 60 min; instead, there appeared to be an increase in transcytosis of the dextran tracer. Furthermore, the imaging results of the exosome study showed an increase in exosome localization in the right hippocampus following 60 min of targeted LIFU.

3 May 2024
Verified
Book Chapter
Closed access
PDF file
SJSheldon Jordan
Sheldon Jordan
JHJonathan Haroon
Jonathan Haroon

16 August 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
JSJean Rama Surya
Jean Rama Surya
BHBarshen Habelhah
Barshen Habelhah
JHJonathan Haroon
Jonathan Haroon
Kennedy MahdaviKennedy Mahdavi
Kennedy Mahdavi
KJKaya Jordan
Kaya Jordan
SJSheldon Jordan
Sheldon Jordan
The present study investigates a potential method of optimizing effective strategies for the functional lateralization of the dorsolateral prefrontal cortex (dlPFC) while in a scanner. Effective hemisphere lateralization of the dlPFC is crucial for lowering the functional risks connected to specific interventions (such as neurosurgery and transcranial magnetic stimulation (TMS), as well as increasing the effectiveness of a given intervention by figuring out the optimal location. This task combines elements of creative problem solving, executive decision making based on an internal rule set, and working memory. A retrospective analysis was performed on a total of 58 unique participants (34 males, 24 females, Mage = 42.93 years, SDage = 16.38). Of these participants, 47 were classified as right-handed, 7 were classified as left-handed, and 4 were classified as ambidextrous, according to the Edinburgh Handedness Inventory. The imaging data were qualitatively judged by two trained, blinded investigators (neurologist and neuropsychologist) for dominant handedness (primary motor cortex) and dominant dorsolateral prefrontal cortex (dlPFC). The results demonstrated that 21.4% of right-handed individuals showed a dominant dlPFC localized to the right hemisphere rather than the assumed left, and 16.7% of left-handers were dominant in their left hemisphere. The task completed in the scanner might be an efficient method for localizing a potential dlPFC target for the purpose of brain stimulation (e.g., TMS), though further study replications are needed to extend and validate these findings.

21 September 2021 in Brain Stimulation
Verified
Journal Article
Open access
JHJonathan Haroon
Jonathan Haroon
KMKennedy Mahdavi
Kennedy Mahdavi
MZMargaret A. Zielinski
Margaret A. Zielinski
BHBarshen Habelhah
Barshen Habelhah
LCLider Chan
Lider Chan
SJSheldon Jordan
Sheldon Jordan

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
DGDayan B. Goodenowe
Dayan B. Goodenowe
JHJonathan Haroon
Jonathan Haroon
MZMargaret A Zielinski
Margaret A Zielinski
KMKennedy D Mahdavi
Kennedy D Mahdavi
BHBarshen Habelhah
Barshen Habelhah
SJSheldon E Jordan
Sheldon E Jordan